Recombinant antibody fusion proteins for cancer immunotherapy

Curr Top Microbiol Immunol. 1996:213 ( Pt 3):27-53. doi: 10.1007/978-3-642-80071-9_3.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Neoplasm / genetics
  • Antibodies, Neoplasm / therapeutic use*
  • Antibody-Dependent Cell Cytotoxicity
  • Cytokines / genetics
  • Cytokines / pharmacokinetics
  • Cytokines / therapeutic use
  • Epidermal Growth Factor / genetics
  • Epidermal Growth Factor / immunology
  • Humans
  • Immunoconjugates / genetics
  • Immunoconjugates / immunology
  • Immunoconjugates / therapeutic use*
  • Immunotherapy, Adoptive
  • Interleukin-2 / genetics
  • Interleukin-2 / therapeutic use
  • Killer Cells, Lymphokine-Activated / immunology
  • Killer Cells, Lymphokine-Activated / transplantation
  • Lymphotoxin-alpha / genetics
  • Lymphotoxin-alpha / therapeutic use
  • Mice
  • Mice, SCID
  • Neoplasm Transplantation
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Neuroblastoma / secondary
  • Neuroblastoma / therapy
  • Recombinant Fusion Proteins / immunology
  • Recombinant Fusion Proteins / pharmacokinetics
  • Recombinant Fusion Proteins / therapeutic use*
  • Superantigens / genetics
  • Superantigens / immunology
  • T-Lymphocytes, Cytotoxic / immunology

Substances

  • Antibodies, Neoplasm
  • Cytokines
  • Immunoconjugates
  • Interleukin-2
  • Lymphotoxin-alpha
  • Recombinant Fusion Proteins
  • Superantigens
  • Epidermal Growth Factor